Compare SHASUN PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA AUROBINDO PHARMA SHASUN PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 123.9 14.3 867.7% View Chart
P/BV x 8.5 3.1 275.1% View Chart
Dividend Yield % 0.2 0.4 57.8%  

Financials

 SHASUN PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
AUROBINDO PHARMA
Mar-18
SHASUN PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs94809 11.6%   
Low Rs46504 9.0%   
Sales per share (Unadj.) Rs214.2281.1 76.2%  
Earnings per share (Unadj.) Rs5.341.4 12.9%  
Cash flow per share (Unadj.) Rs15.850.9 31.1%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %1.40.4 375.7%  
Book value per share (Unadj.) Rs53.3199.4 26.8%  
Shares outstanding (eoy) m56.62585.88 9.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.3 14.0%   
Avg P/E ratio x13.115.9 82.5%  
P/CF ratio (eoy) x4.412.9 34.2%  
Price / Book Value ratio x1.33.3 39.8%  
Dividend payout %18.76.0 310.0%   
Avg Mkt Cap Rs m3,958384,630 1.0%   
No. of employees `000NA17.3 0.0%   
Total wages/salary Rs m2,16421,308 10.2%   
Avg. sales/employee Rs ThNM9,500.7-  
Avg. wages/employee Rs ThNM1,229.4-  
Avg. net profit/employee Rs ThNM1,397.9-  
INCOME DATA
Net Sales Rs m12,127164,666 7.4%  
Other income Rs m2291,020 22.5%   
Total revenues Rs m12,356165,686 7.5%   
Gross profit Rs m1,00937,718 2.7%  
Depreciation Rs m5945,580 10.6%   
Interest Rs m415777 53.4%   
Profit before tax Rs m23032,380 0.7%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-738,183 -0.9%   
Profit after tax Rs m30224,229 1.2%  
Gross profit margin %8.322.9 36.3%  
Effective tax rate %-31.725.3 -125.3%   
Net profit margin %2.514.7 16.9%  
BALANCE SHEET DATA
Current assets Rs m6,884121,878 5.6%   
Current liabilities Rs m8,45686,806 9.7%   
Net working cap to sales %-13.021.3 -60.8%  
Current ratio x0.81.4 58.0%  
Inventory Days Days62130 47.5%  
Debtors Days Days10868 157.3%  
Net fixed assets Rs m4,97081,037 6.1%   
Share capital Rs m113586 19.3%   
"Free" reserves Rs m2,875116,218 2.5%   
Net worth Rs m3,020116,804 2.6%   
Long term debt Rs m1,8174,512 40.3%   
Total assets Rs m13,347211,052 6.3%  
Interest coverage x1.642.7 3.6%   
Debt to equity ratio x0.60 1,557.8%  
Sales to assets ratio x0.90.8 116.5%   
Return on assets %5.411.8 45.4%  
Return on equity %10.020.7 48.2%  
Return on capital %13.327.4 48.7%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84380,727 7.2%   
Fx outflow Rs m2,17334,700 6.3%   
Net fx Rs m3,66946,027 8.0%   
CASH FLOW
From Operations Rs m39819,548 2.0%  
From Investments Rs m-1,635-19,570 8.4%  
From Financial Activity Rs m1,3098,642 15.1%  
Net Cashflow Rs m718,922 0.8%  

Share Holding

Indian Promoters % 39.2 54.1 72.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 8.0 45.3%  
FIIs % 17.6 27.7 63.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.2 388.2%  
Shareholders   20,750 69,601 29.8%  
Pledged promoter(s) holding % 12.3 8.6 143.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS